Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (P30MH092177, R01MH110360, P30MH062261)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P01DA037830, R01DA042706)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS036126, R01NS034239)
Received: 15 November 2018
Accepted: 22 April 2019
First Online: 2 July 2019
: K.K. and RK are named inventors on patents that cover the viral gene editing technology that is the subject of this article. HEG and BE are named inventors on patents that cover the medicinal and polymer chemistry technologies that were also employed in this manuscript. In addition to the foregoing interests, KK is a co-founder, board member, scientific advisor, and holds equity in Excision Biotherapeutics, a biotech start-up that has licensed the viral gene editing technology from Temple University for commercial development and clinical trials. H.E.G. is the founder of Brain First, a second independent biotech start-up and is the operative head of the Nebraska Nanomedicine Production Plant, a good manufacturing program facility that was responsible for synthesizing the long-acting slow effective release antiretroviral therapies used in the accompanying report. The authors declare that this work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work including, but not limited to, the study conception and design; data acquisition, analysis and interpretation; and writing of the manuscript. No other entities provided funds for the work. The authors further declare that they have received no financial compensation from any other third parties for any aspects of the published work. The remaining authors declare no competing interests.